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Cochrane corner: beta-blockers 
for hypertension
Charles S Wiysonge,1 Hazel A Bradley,2 Jimmy Volmink,3 
Bongani M Mayosi4,5
BaCkground
Beta-blockers refer to an assorted group of 
medications that block the action of endog-
enous catecholamines on beta-adrenergic 
receptors.1 The β1 and β2 receptors are 
the primary beta-adrenergic receptors in 
the human cardiovascular system. Beta-
blockers differ in their β1/β2-receptor 
selectivity and vasodilatory properties. 
Based on this diversity, beta-blockers have 
been categorised into first, second and 
third generation. First-generation beta-
blockers, also referred to as non-selective 
blockers, possess equal affinity for β1 and 
β2 receptors. Second-generation (or selec-
tive) beta-blockers exercise more affinity 
for β1 than β2 receptors. Neither of these 
traditional beta-blockers has vasodilatory 
properties, which is an intrinsic character-
istic of third-generation beta-blockers.2
Beta-blockers have been known to play 
a role in blood pressure control since 
1949.3 We summarise the findings of a 
Cochrane Review we published in 2017 on 
the comparative effects of beta-blockers as 
initial treatment for hypertension.4 This is 
an update of a review we first published 
10 years ago.5–7
Concise methods
We searched the Cochrane Library, 
MEDLINE, EMBASE and  ClinicalTrials. 
gov using a comprehensive database-spe-
cific search string and checked reference 
lists of relevant publications, up to June 
2016. We selected randomised trials with 
a duration of at least 12 months, which 
assessed the effects of beta-blockers as first-
line therapy for hypertension, compared 
with placebo or other antihyperten-
sive drugs. Eligible studies had to report 
one or more of the following outcomes: 
all-cause mortality, stroke, coronary heart 
disease, cardiovascular death and cardio-
vascular events (ie, coronary heart disease, 
strokes and heart failure). We used stan-
dard Cochrane methods to select eligible 
studies, assess risk of bias, extract and 
analyse data and assess the certainty of the 
evidence.7
Main results
Thirteen studies met our inclusion criteria. 
These studies compared beta-blockers with 
placebo or no treatment (four studies), 
diuretics (five studies), calcium-channel 
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table 1 Summary of main results
outcomes risk ratio (95% Ci)
no of participants (no of 
studies) Certainty of the evidence
Beta-blockers versus placebo
  All-cause mortality 0.99 (0.88 to 1.11) 23 613 (4 studies) ⊕⊕⊕⊝
Moderate*
  Cardiovascular events 0.88 (0.79 to 0.97) 23 613 (4 studies) ⊕⊕⊝⊝
Low*†
  Stroke 0.80 (0.66 to 0.96) 23 613 (4 studies) ⊕⊕⊝⊝
Low*†
  Coronary heart disease 0.93 (0.81 to 1.07) 23 613 (4 studies) ⊕⊕⊕⊝
Moderate*
  Adverse events 3.38 (0.82 to 13.95) 22 729 (3 studies) ⊕⊕⊝⊝
Low‡
Beta-blockers versus diuretics
  All-cause mortality 1.04 (0.91 to 1.19) 18 241 (5 studies) ⊕⊕⊕⊝
Moderate*
  Cardiovascular events 1.13 (0.99 to 1.28) 18 135 (4 studies) ⊕⊕⊕⊝
Moderate*
  Stroke 1.17 (0.65 to 2.09) 18 135 (4 studies) ⊕⊕⊝⊝
Low*‡
  Coronary heart disease 1.12 (0.82 to 1.54) 18 135 (4 studies) ⊕⊕⊝⊝
Low*‡
  Adverse events 1.69 (0.95 to 3.00) 11 566 (3 studies) ⊕⊕⊝⊝
Low*‡
Beta-blockers versus calcium-channel blockers
  All-cause mortality 1.07 (1.0 to 1.14) 44 825 (4 studies) ⊕⊕⊕⊝
Moderate†
  Cardiovascular events 1.18 (1.08 to 1.29) 19 915 (2 studies) ⊕⊕⊕⊝
Moderate§
  Stroke 1.24 (1.11 to 1.4) 44 167 (3 studies) ⊕⊕⊕⊝
Moderate§
  Coronary heart disease 1.05 (0.96 to 1.15) 44 167 (3 studies) ⊕⊕⊕⊝
Moderate§
  Adverse events 1.20 (0.71 to 2.04) 21 591 (2 studies) ⊕⊕⊝⊝
Low‡§
Beta-blockers versus renin–angiotensin system inhibitors
  All-cause mortality 1.10 (0.98 to 1.24) 10 828 (3 studies) ⊕⊕⊕⊝
Moderate§
  Cardiovascular events 1.0 (0.72 to 1.38) 10 828 (3 studies) ⊕⊕⊝⊝
Low‡§
  Stroke 1.30 (1.11 to 1.53) 9951 (2 studies) ⊕⊕⊕⊝
Moderate§
  Coronary heart disease 0.90 (0.76 to 1.06) 9951 (2 studies) ⊕⊕⊝⊝
Low§¶
  Adverse events 1.41 (1.29 to 1.54) 9951 (2 studies) ⊕⊕⊕⊝
Moderate§
*The two studies that contribute the most weight to this finding have high risk of bias.
†The risk ratio is too close to 1 and could easily include 1 if more trials are added.
‡Substantial heterogeneity of effect across studies.
§Only two to three studies have reported data on this outcome.
¶Imprecise results with a wide CI.
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blockers (four studies) and renin–angio-
tensin system inhibitors (three studies). 
Ten studies enrolled both men and women 
and the rest enrolled only men. Six studies 
enrolled participants aged 65 years or 
younger and the others enrolled partici-
pants aged 18 to 70 years (one study), 40 
to 79 years (one study), 45 to 75 years (one 
study), more than 50 years (one study), 
55 to 80 years (one study), 60 to 79 years 
(study) and 65 to 74 years (one study).
Most studies were conducted in Western 
Europe and North America. Among the 
nine studies that provided data on race, 
the proportion of participants categorised 
as white was 0% (one study), 44% to 48% 
(two studies) and 86% to 100% (six studies). 
We adjudicated most studies to have a high 
risk of bias because of weaknesses in study 
design, conduct and data analysis.
Table 1 shows the summary of beta-
blocker effects on key outcomes. When 
used as initial treatment for hypertension, 
there is low-certainty evidence that beta-
blockers may reduce the risk of cardio-
vascular events compared with placebo. 
This beneficial effect is a reflection of 
the substantial reduction in strokes with 
beta-blockers since there is little or no 
difference in coronary events between 
patients on beta-blockers and those on 
placebo. There is moderate-certainty 
evidence that this effect of beta-blockers 
on cardiovascular events is similar to 
that of diuretics and renin–angiotensin 
system inhibitors, but it is inferior to 
that of calcium-channel blockers. In 
addition, there is moderate-certainty 
evidence that calcium-channel blockers 
and renin–angiotensin system inhibitors 
prevent strokes more than beta-blockers. 
However, there is moderate-certainty 
evidence that beta-blockers have little 
or no effect on all-cause mortality when 
used as initial treatment for hypertension. 
This effect of beta-blockers on mortality 
is identical to that of diuretics and 
renin–angiotensin system inhibitors, but 
it is inferior to that of calcium-channel 
blockers. Finally, there is low-certainty 
evidence that hypertensive patients on 
beta-blockers are more likely to discon-
tinue medications due to adverse events 
than patients on renin–angiotensin 
system inhibitors. Nonetheless, there is 
little or no difference in adverse events 
between beta-blockers and diuretics or 
calcium-channel blockers.
Overall, treatment of hypertension leads 
to reductions in cardiovascular events 
with the degree of reduction depen-
dent on the type of medication used to 
initiate treatment. Starting therapy with 
calcium-channel blockers or renin–angio-
tensin system inhibitors produces higher 
declines in cardiovascular events than with 
beta-blockers.
liMitations
All included studies added other antihyper-
tensive medications to the initial therapy. 
Thus, it is possible that the suboptimal 
effects seen with first-line beta-blockers 
could have resulted from the additional 
medications used. Atenolol (a second-gen-
eration or selective beta-blocker) was the 
beta-blocker used in three-quarters of 
participants in beta-blocker arms. Thus, it 
is not possible to say whether the subop-
timal effectiveness and safety seen with 
beta-blockers is a property of atenolol or 
is a class effect of all beta-blockers. We did 
not find any trials that assessed the effects 
of vasodilatory beta-blockers in preventing 
mortality or cardiovascular events. The 
certainty of the evidence for most outcomes 
was low, implying that the likelihood of 
further research finding the effect of beta-
blockers to be substantially different from 
the results of this review is high.
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